Conversion of alpha 1-antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities.

Despite the homology with alpha 1-protease inhibitor (alpha 1PI), wild-type antichymotrypsin (ACT) is a substrate for HNE rather than an inhibitor of the enzyme. In order to investigate the nature of the specificity between serpins and serine proteases, the reactions of human neutrophil elastase (HNE) with wild-type recombinant ACT and recombinant variants of ACT were studied. ACT variants were generated where (1) the primary interaction site, the P1 position, was replaced with the P1 residue of alpha 1PI, (2) the residues corresponding to P3-P3' were replaced with those of alpha 1PI, and (3) the residues corresponding to the canonical recognition sequence as well as flanking residues encompassing the exposed reactive loop of the inhibitor were replaced with the corresponding residues of alpha 1PI. Each variant was analyzed to determine the effect of the replacements on reactions with human neutrophil elastase and chymotrypsin with regard to (1) the second-order rate constant for enzyme-serpin complex formation, (2) the number of moles of serpin required to completely inhibit 1 mol of enzyme (the stoichiometry of inhibition, SI), and (3) the stability of the enzyme-serpin complex. Replacing Leu with Met in the P1 position (rACT-L358M) was sufficient to convert rACT into an inhibitor of HNE with an apparent second-order rate constant (k'/[I]) of 4 x 10(4) M-1 s-1 and an SI of 5. The high SI was due to a concurrent hydrolytic reaction at sites in the reactive loop.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  P. Grootenhuis,et al.  Dissociation of heparin-dependent thrombin and factor Xa inhibitory activities of antithrombin-III by mutations in the reactive site. , 1993, The Journal of biological chemistry.

[2]  D. Speicher,et al.  Microsequence analysis of electroblotted proteins. II. Comparison of sequence performance on different types of PVDF membranes. , 1992, Analytical biochemistry.

[3]  D. Speicher,et al.  Microsequence analysis of electroblotted proteins. I. Comparison of electroblotting recoveries using different types of PVDF membranes. , 1992, Analytical biochemistry.

[4]  S. Olson,et al.  Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. , 1992, The Journal of biological chemistry.

[5]  D. Vaughan,et al.  Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. , 1992, The Journal of biological chemistry.

[6]  P. Enriquez,et al.  Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes. , 1992, The Journal of biological chemistry.

[7]  J. Potempa,et al.  Proteolytic inactivation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity. , 1991, The Journal of biological chemistry.

[8]  P. Stein,et al.  Mobile reactive centre of serpins and the control of thrombosis , 1991, Nature.

[9]  J. Beechem,et al.  Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. , 1991, Biochemistry.

[10]  J. Travis,et al.  Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions. , 1991, Journal of Biological Chemistry.

[11]  J M Thornton,et al.  Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors. , 1991, Journal of molecular biology.

[12]  W. R. Wikoff,et al.  Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status. , 1991, Journal of Biological Chemistry.

[13]  B. Cooperman,et al.  Inhibition of human neutrophil superoxide generation by alpha 1-antichymotrypsin. , 1991, Journal of immunology.

[14]  Robert Huber,et al.  Ligand binding: proteinase-protein inhibitor interactions , 1991 .

[15]  J. Travis,et al.  Acute phase protein stimulation by alpha 1-antichymotrypsin-cathepsin G complexes. Evidence for the involvement of interleukin-6. , 1990, The Journal of biological chemistry.

[16]  D. Lawrence,et al.  Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. , 1990, The Journal of biological chemistry.

[17]  R. Huber,et al.  Structural transition of α1‐antitrypsin by a peptide sequentially similar to β‐strand s4A , 1990 .

[18]  A. Leslie,et al.  Crystal structure of ovalbumin as a model for the reactive centre of serpins , 1990, Nature.

[19]  F. Church,et al.  Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. , 1990, The Journal of biological chemistry.

[20]  B. Cooperman,et al.  Cloning, expression, purification, and biological activity of recombinant native and variant human alpha 1-antichymotrypsins. , 1990, The Journal of biological chemistry.

[21]  B. Cooperman,et al.  Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. , 1989, The Journal of biological chemistry.

[22]  F. Church,et al.  Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. , 1989, Blood.

[23]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[24]  W. Bode,et al.  Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. , 1989, Biochemistry.

[25]  M. Padrines,et al.  Inhibition of neutrophil elastase by alpha-1-proteinase inhibitor oxidized by activated neutrophils. , 1989, The American review of respiratory disease.

[26]  R. Senior,et al.  The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant , 1988, The Journal of experimental medicine.

[27]  B. Wiman,et al.  Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. , 1988, The Biochemical journal.

[28]  R. Senior,et al.  Alpha 1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. , 1988, The Journal of biological chemistry.

[29]  R. Crystal,et al.  Altered specificities of genetically engineered α1 antitrypsin variants , 1986 .

[30]  R. Carrell,et al.  Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis , 1985, Nature.

[31]  R. Carrell,et al.  α1-Antitrypsin and the serpins: variation and countervariation , 1985, Trends in Biochemical Sciences.

[32]  I. Clemmensen,et al.  Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitor. , 1981, The Biochemical journal.

[33]  J. Travis,et al.  Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. , 1980, The Journal of biological chemistry.

[34]  K. Orre,et al.  The production of an inactive form of antithrombin through limited proteolysis by thrombin , 1979, FEBS letters.

[35]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[36]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.